We know that a molecule—interleukin-1beta—is at the root of many serious inflammatory diseases, including rheumatoid arthritis, atherosclerosis, Type 2 diabetes, and certain types of stroke. But how the body produces this molecule was never clear—until now. A group of Cedars-Sinai researchers recently identified the mechanism by which interleukin is produced—a groundbreaking discovery that could lead to advances in treating chronic diseases that afflict more than 100 million people in the U.S.
Current drug therapies seek to block interleukin’s action after cells secrete it. “Now that we understand how this molecule is made in the body, we may be able to block it before it is produced,” says study author Moshe Arditi, MD, director of the Division of Pediatric Infectious Diseases, Allergy and Immunology at Cedars-Sinai.
The discovery may make it possible to treat certain diseases in their early stages, before symptoms become severe and debilitating.